{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:45:02Z","timestamp":1772765102795,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["NIH T32 GM06669"],"award-info":[{"award-number":["NIH T32 GM06669"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K08 CA237624"],"award-info":[{"award-number":["K08 CA237624"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"U.S. Department of Defense","award":["W81XWH-20-1-0605"],"award-info":[{"award-number":["W81XWH-20-1-0605"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00432-022-04299-1","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T09:11:07Z","timestamp":1663146667000},"page":"877-883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team"],"prefix":"10.1007","volume":"149","author":[{"given":"Christopher","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura C.","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy K.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"4299_CR1","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol off J Am Soc Clin Oncol 36:1714\u20131768","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"4299_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR et al (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer 9:e002435","journal-title":"J. Immunother. Cancer"},{"key":"4299_CR3","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ajg.2014.131","volume":"109","author":"NP Chalasani","year":"2014","unstructured":"Chalasani NP et al (2014) ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 109:950\u2013966 (quiz 967)","journal-title":"Am J Gastroenterol"},{"key":"4299_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","volume":"10","author":"V Cheung","year":"2019","unstructured":"Cheung V et al (2019) Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol 10:364\u2013371","journal-title":"Frontline Gastroenterol"},{"key":"4299_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E et al (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68:1181\u20131190","journal-title":"J Hepatol"},{"key":"4299_CR6","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","volume":"184","author":"M Dougan","year":"2021","unstructured":"Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW (2021a) Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 184:1575\u20131588","journal-title":"Cell"},{"key":"4299_CR7","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","volume":"160","author":"M Dougan","year":"2021","unstructured":"Dougan M, Wang Y, Rubio-Tapia A, Lim JK (2021b) AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 160:1384\u20131393","journal-title":"Gastroenterology"},{"key":"4299_CR8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"EASL Clinical Practice Guidelines","year":"2015","unstructured":"EASL Clinical Practice Guidelines (2015) Autoimmune hepatitis. J Hepatol 63:971\u20131004","journal-title":"J Hepatol"},{"key":"4299_CR9","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092","journal-title":"N Engl J Med"},{"key":"4299_CR10","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 28:iv119\u2013iv142","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"4299_CR11","doi-asserted-by":"publisher","first-page":"vii17","DOI":"10.1093\/rheumatology\/kez465","volume":"58","author":"H Ibraheim","year":"2019","unstructured":"Ibraheim H, Perucha E, Powell N (2019) Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatol Oxf Engl 58:vii17\u2013vii28","journal-title":"Rheumatol Oxf Engl"},{"key":"4299_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/17425255.2019.1574744","volume":"15","author":"JJ Jennings","year":"2019","unstructured":"Jennings JJ, Mandaliya R, Nakshabandi A, Lewis JH (2019) Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol 15:231\u2013244","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4299_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","volume":"39","author":"M Johncilla","year":"2015","unstructured":"Johncilla M et al (2015) Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 39:1075\u20131084","journal-title":"Am J Surg Pathol"},{"key":"4299_CR14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","volume":"31","author":"KW Kim","year":"2013","unstructured":"Kim KW et al (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31:1071\u20131077","journal-title":"Invest New Drugs"},{"key":"4299_CR15","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jamaoncol.2021.4342","volume":"7","author":"M Li","year":"2021","unstructured":"Li M et al (2021) Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer. JAMA Oncol 7:1711\u20131714","journal-title":"JAMA Oncol"},{"key":"4299_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/hep.32215","volume":"75","author":"M Li","year":"2022","unstructured":"Li M et al (2022) Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatol Baltim Md 75:531\u2013540","journal-title":"Hepatol Baltim Md"},{"key":"4299_CR17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.6004\/jnccn.2018.7268","volume":"17","author":"J Naidoo","year":"2019","unstructured":"Naidoo J et al (2019) A multidisciplinary toxicity team for cancer immunotherapy-related adverse events. J Natl Compr Cancer Netw JNCCN 17:712\u2013720","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"4299_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.5858\/arpa.2020-0070-RA","volume":"145","author":"PA Patil","year":"2021","unstructured":"Patil PA, Zhang X (2021) Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy. Arch Pathol Lab Med 145:571\u2013582","journal-title":"Arch Pathol Lab Med"},{"key":"4299_CR19","doi-asserted-by":"publisher","first-page":"1875639","DOI":"10.1080\/2162402X.2021.1875639","volume":"10","author":"JRJ Patrinely","year":"2021","unstructured":"Patrinely JRJ et al (2021) A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology 10:1875639","journal-title":"Oncoimmunology"},{"key":"4299_CR20","first-page":"1657","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares L et al (2020) A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 15:1657\u20131669","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"4299_CR21","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol Off J Am Soc Clin Oncol 39:4073\u20134126","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04299-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04299-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04299-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T07:11:55Z","timestamp":1676617915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04299-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["4299"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04299-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"11 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CF is supported by an NIH T32 GM066691. JN is supported by Merck, Astrazeneca, BMS, Amgen, Novartis, Roche\/Genentech and on the consulting\/advisory board of: Merck, Astrazeneca, BMS, Amgen, Novartis, Roche\/Genentech, Takeda, Pfizer, Daiichi Sankyo, NGM biosciences. LCC provides consulting and has research funding support from Bristol-Myers Squibb. JRB is an advisory board member of Amgen, BMS, Genentech, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, AstraZeneca, Regeneron and receives funding support from: AstraZeneca, BMS, Genentech, RAPT Therapeutics, Inc., Revolution Medicine and is a DSMB member\u00a0of Sanofi, GlaxoSmithKline, Janssen. RAA is a consultant for Bristol Myers Squib. AKK is supported by NCI K08 CA237624 and DoD Award W81XWH-20-1-0605, Exelixis and AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}